Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1608018

registered interest
date	27/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access: Disclosure of Information
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his Department’s ongoing VPAS pre-negotiation workshops, if he will publish the (a) minutes and (b) attendees of those workshops.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	174320
answer	answer is ministerial correction date of answer 30/03/2023 answer text <p>The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme for branded medicines pricing and access (VPAS) upon the different organisations represented and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 VPAS. In order to facilitate a transparent and candid discussion, participants agreed that all contributions and resulting outputs would be kept confidential to those who attended.</p><p>The following organisations were invited to the workshops:</p><p>Industry bodies (including representatives of their member companies):</p><p>- Association of the British Pharmaceutical Industry;</p><p>- British Generic Manufacturers Association;</p><p>- Ethical Medicines Industry Group;</p><p>- BioIndustry Association.</p><p>Patient organisations and civil society organisations:</p><p>- Cancer52;</p><p>- The Blood Cancer Alliance;</p><p>- The Charity Medicines Access Coalition;</p><p>- National Voices;</p><p>- The Patients Association;</p><p>- Alzheimer’s Research UK;</p><p>- Anthony Nolan;</p><p>- Cystic Fibrosis Trust;</p><p>- Genetic Alliance UK;</p><p>- The Association of Medical Research Charities;</p><p>- Breast Cancer Now;</p><p>- Myeloma UK;</p><p>- Office of Health Economics;</p><p>- King’s Fund;</p><p>- NHS Confederation.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 174321 question first answered 30/03/2023 15:18:28 answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner

1608020

registered interest
date	27/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access: Disclosure of Information
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his Department’s ongoing VPAS pre-negotiation workshops, whether he plans to make the outputs of those discussions publicly available.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	174321
answer	answer is ministerial correction date of answer 30/03/2023 answer text <p>The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme for branded medicines pricing and access (VPAS) upon the different organisations represented and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 VPAS. In order to facilitate a transparent and candid discussion, participants agreed that all contributions and resulting outputs would be kept confidential to those who attended.</p><p>The following organisations were invited to the workshops:</p><p>Industry bodies (including representatives of their member companies):</p><p>- Association of the British Pharmaceutical Industry;</p><p>- British Generic Manufacturers Association;</p><p>- Ethical Medicines Industry Group;</p><p>- BioIndustry Association.</p><p>Patient organisations and civil society organisations:</p><p>- Cancer52;</p><p>- The Blood Cancer Alliance;</p><p>- The Charity Medicines Access Coalition;</p><p>- National Voices;</p><p>- The Patients Association;</p><p>- Alzheimer’s Research UK;</p><p>- Anthony Nolan;</p><p>- Cystic Fibrosis Trust;</p><p>- Genetic Alliance UK;</p><p>- The Association of Medical Research Charities;</p><p>- Breast Cancer Now;</p><p>- Myeloma UK;</p><p>- Office of Health Economics;</p><p>- King’s Fund;</p><p>- NHS Confederation.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 174320 question first answered 30/03/2023 15:18:28 answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner

1604911

registered interest
date	16/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish (a) the minutes from and (b) a list of attendees at the workshops his Department has been running ahead of negotiations on a new Voluntary Scheme for Branded Medicines Pricing and Access.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	167135
answer	answer is ministerial correction date of answer 23/03/2023 answer text <p>The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme upon the different organisations represented, and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 voluntary scheme for branded medicines pricing and access. In order to facilitate a transparent and candid discussion, participants agreed that all contributions would be kept confidential to those who attended.</p><p>The following external organisations were invited to the workshops:</p><p>Industry bodies:</p><p>- Association of the British Pharmaceutical Industry</p><p>- British Generic Manufacturers Association</p><p>- Ethical Medicines Industry Group</p><p>- BioIndustry Association</p><p>Patient organisations and civil society organisations:</p><p>- Cancer52</p><p>- The Blood Cancer Alliance</p><p>- The Charity Medicines Access Coalition</p><p>- National Voices</p><p>- The Patients Association</p><p>- Alzheimer’s Research UK</p><p>- Anthony Nolan</p><p>- Cystic Fibrosis Trust</p><p>- Genetic Alliance UK</p><p>- The Association of Medical Research Charities</p><p>- Breast Cancer Now</p><p>- Myeloma UK</p><p>- Office of Health Economics</p><p>- King’s Fund</p><p>- NHS Confederation</p><p> </p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 167136 question first answered 23/03/2023 16:20:08 answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner

1604912

registered interest
date	16/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to publish information about the outcomes from the workshops that his Department has been running ahead of negotiations on a new Voluntary Scheme for Branded Medicines Pricing and Access.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	167136
answer	answer is ministerial correction date of answer 23/03/2023 answer text <p>The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme upon the different organisations represented, and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 voluntary scheme for branded medicines pricing and access. In order to facilitate a transparent and candid discussion, participants agreed that all contributions would be kept confidential to those who attended.</p><p>The following external organisations were invited to the workshops:</p><p>Industry bodies:</p><p>- Association of the British Pharmaceutical Industry</p><p>- British Generic Manufacturers Association</p><p>- Ethical Medicines Industry Group</p><p>- BioIndustry Association</p><p>Patient organisations and civil society organisations:</p><p>- Cancer52</p><p>- The Blood Cancer Alliance</p><p>- The Charity Medicines Access Coalition</p><p>- National Voices</p><p>- The Patients Association</p><p>- Alzheimer’s Research UK</p><p>- Anthony Nolan</p><p>- Cystic Fibrosis Trust</p><p>- Genetic Alliance UK</p><p>- The Association of Medical Research Charities</p><p>- Breast Cancer Now</p><p>- Myeloma UK</p><p>- Office of Health Economics</p><p>- King’s Fund</p><p>- NHS Confederation</p><p> </p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 167135 question first answered 23/03/2023 16:20:08 answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner

1585251

registered interest
date	08/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the UK's share of the global pharmaceutical research and development market.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	142722
answer	answer is ministerial correction date of answer 24/02/2023 answer text <p>The Department, alongside the former Department of Business, Energy and Industrial Strategy, have jointly commissioned an independent review of clinical trials. The review, currently underway, will offer recommendations on how commercial clinical trials can help the life sciences sector unlock United Kingdom growth and investment opportunities. It will also advise on how to resolve key challenges in conducting commercial clinical trials in the UK and will build on the 2021 publication of ‘Saving and Improving Lives: The Future of UK Clinical Research Delivery’. This vision sets out plans restructuring the UK’s research delivery to enable increased recruitment and market share of global trial numbers and aims to make study set-up and delivery faster, more efficient and more innovative. All of these measures will offer the assurance to global pharmaceutical companies that the UK remains one of the best places in the world to deliver cutting-edge research and increase the share of the global pharmaceutical research and development market.</p> answering member constituency Colchester answering member printed Will Quince question first answered 24/02/2023 12:03:48 answering member 4423 label Biography information for Will Quince previous answer version 56368 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner

1585252

registered interest
date	08/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to help streamline processes for future medical innovations so they are available in similar timeframes to covid-19 treatments.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	142723
answer	answer is ministerial correction date of answer 20/02/2023 answer text <p>The Government is committed to supporting timely patient access to promising and innovative new treatments. Our Life Science Vision published in 2021 set out our ambition to build on the scientific successes and ways of working from COVID-19 to tackle the biggest disease challenges.</p><p>The United Kingdom’s participation in Project Orbis and the creation of the Innovative Licensing and Access Pathway (ILAP) are already enabling the more rapid review and approval of promising new medicines. In addition, the National Institute for Health and Care Excellence is introducing a more proportionate approach to appraisals that will create more flexibility in its medicine evaluation processes and speed up access for patients.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/02/2023 10:20:37 answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner

1585253

registered interest
date	08/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department are taking to learn from best practice used during (a) the Covid-19 vaccination programme and (b) the response to the Covid-19 pandemic.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	142724
answer	answer is ministerial correction date of answer 20/02/2023 answer text <p>The United Kingdom’s vaccination programme, from research and development of vaccines against COVID-19 to the deployment to over 93% of the adult population aged 12 years old and over (as of 7 June 2022), has been one of the most successful and effective initiatives in the history of UK science and public administration. The Government is taking steps to learn from the best practice used during this programme.</p><p> </p><p>The Centre for Pandemic Preparedness within the UK Health Security Agency is working with partners in Government, academia and industry to understand the findings from evaluation of COVID-19 policies and exercises to identify lessons we can learn from for future incidents. We will also review the evidence base underpinning different policies and identify gaps.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 20/02/2023 10:40:11 answering member 4492 label Biography information for Maria Caulfield
tabling member	4382 label Biography information for Daniel Zeichner

1585254

registered interest
date	08/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department are taking to improve (a) the uptake of and (b) access to Covid-19 treatments.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	142725
answer	answer is ministerial correction date of answer 20/02/2023 answer text <p>In England, eligible patients who test positive for COVID-19 will be contacted by a clinician from a COVID Medicines Delivery Unit (CMDU) to discuss treatment suitability. The clinician will be responsible for assessing the patient and deciding which treatment option is most appropriate for them. Guidance has been provided to general practitioners, NHS 111 and hospital doctors to ensure information is available to support patients.</p><p>Currently, immunocompromised patients who form part of the high-risk cohort are eligible for receiving COVID-19 treatments within the community following a positive test. The Therapeutics Clinical Review Panel has been established to review the patient cohorts which could be eligible for COVID-19 therapies. On 30 May 2022 the Department published an Independent Advisory Group report which revised the high-risk cohort and included additional groups of patients. As a result of these changes and improved identification by the National Health Service, the cohort of eligible patients has grown to an estimated 1.8 million patients in the United Kingdom. Access to treatments could be extended further if evidence from clinical trials supports doing so. The PANORAMIC study aims to improve understanding of the effectiveness antivirals in preventing hospitalisation and/or death in a largely vaccinated population will provide data for the NHS to determine which patient groups could benefit most from antiviral treatments.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 142726 question first answered 20/02/2023 09:21:53 answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner

1585255

registered interest
date	08/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to (a) improve (i) awareness of and (ii) access to Covid-19 antivirals for people who are eligible to receive them and (b) review the eligibility criteria for Covid-19 antivirals.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	142726
answer	answer is ministerial correction date of answer 20/02/2023 answer text <p>In England, eligible patients who test positive for COVID-19 will be contacted by a clinician from a COVID Medicines Delivery Unit (CMDU) to discuss treatment suitability. The clinician will be responsible for assessing the patient and deciding which treatment option is most appropriate for them. Guidance has been provided to general practitioners, NHS 111 and hospital doctors to ensure information is available to support patients.</p><p>Currently, immunocompromised patients who form part of the high-risk cohort are eligible for receiving COVID-19 treatments within the community following a positive test. The Therapeutics Clinical Review Panel has been established to review the patient cohorts which could be eligible for COVID-19 therapies. On 30 May 2022 the Department published an Independent Advisory Group report which revised the high-risk cohort and included additional groups of patients. As a result of these changes and improved identification by the National Health Service, the cohort of eligible patients has grown to an estimated 1.8 million patients in the United Kingdom. Access to treatments could be extended further if evidence from clinical trials supports doing so. The PANORAMIC study aims to improve understanding of the effectiveness antivirals in preventing hospitalisation and/or death in a largely vaccinated population will provide data for the NHS to determine which patient groups could benefit most from antiviral treatments.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 142725 question first answered 20/02/2023 09:21:53 answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner

1585256

registered interest
date	08/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Infectious Diseases: Disease Control
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to use (a) vaccination and (b) other treatments, including antivirals amongst vulnerable groups in winter 2023.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	142727
answer	answer is ministerial correction date of answer 28/02/2023 answer text <p>On 25 January 2023, the Government accepted interim advice from the JCVI to plan to offer a COVID-19 vaccine booster dose in autumn 2023 to those at higher risk of severe COVID-19. The Government will confirm the approach to autumn vaccination for COVID-19 once final advice is received from the JCVI later this year.</p><p> </p><p>JCVI’s 2023/24 seasonal influenza (flu) advice was published on 30 November 2022 confirming its advice on which vaccines should be prioritised for various at-risk groups. NHS England will publish the 2023/24 reimbursement letter and the UK Health Security Agency (UKHSA) will publish the annual flu letter in due course. These will set out details about which cohorts will be offered a free flu vaccine and which vaccines they will be offered.</p><p>Respiratory syncytial virus (RSV) is a common respiratory virus that can be serious, especially for infants. An RSV monoclonal antibody is offered to a very small group of at-risk infants from each autumn which is the beginning of the annual RSV season. The JCVI is reviewing new products for potentially improving and expanding the RSV immunisation offer. The Government will announce these in due course.</p><p>COVID-19 patients in England whose immune system means they are at the highest risk from COVID-19, and who test positive for the virus, can currently directly access antiviral treatments through the National Health Service at any time of year. For flu, the UKHSA will recommend the appropriate timing for antiviral medicines to be prescribed and supplied in both primary and secondary care for patients in clinical at-risk group.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 28/02/2023 17:08:25 answering member 4492 label Biography information for Maria Caulfield previous answer version 56364 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
tabling member	4382 label Biography information for Daniel Zeichner